AI Science Tracker
EN

Incremental value of radiomics with machine learning to the existing prognostic models for predicting outcome in renal cell carcinoma

Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China · 28 Apr 2023 · medicine

Discovery

Incremental value of radiomics with machine learning to the existing prognostic models for predicting outcome in renal cell carcinoma

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: Across 689 patients, the radiomics nomogram added prognostic value over existing clinical models.

Technology: Random forest and LASSO-Cox selected CT radiomics for a renal-cell-carcinoma survival nomogram.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Random forest and LASSO-Cox selected CT radiomics for a renal-cell-carcinoma survival nomogram.
Limitation / still unknown
Training plus two validation cohorts and survival discrimination/calibration analyses; retrospective result does not establish treatment benefit.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1036734/full · https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1036734/full#s2 · https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1036734/full#s3–s4 · https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1036734/full#s2–s4 · https://pubmed.ncbi.nlm.nih.gov/37188171/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.